Key result
Intravenous allopurinol decreased myocardial oxygen consumption by 49% (P=0.002) and increased mechanical efficiency by 122% (P=0.04) in dogs with pacing-induced heart failure.
Why the study?
Does intravenous allopurinol improve inotropic properties and mechanical efficiency without increasing myocardial oxygen consumption in dogs with pacing-induced heart failure?
Does intravenous allopurinol improve inotropic properties and mechanical efficiency without increasing myocardial oxygen consumption in dogs with pacing-induced heart failure?
Effect estimate: -49%
p-value: p=0.002
Allopurinol acts as a unique inotrope in a canine model of heart failure, increasing contractility while simultaneously reducing myocardial oxygen consumption and boosting mechanical efficiency.
No takes yet. Share an insight, caveat, or question.
Should not change clinical HF management; extends experimental evidence on allopurinol's energetics to warrant human translation studies.
Ekelund et al. (1999) studied Pacing-induced heart failure (n=15). Allopurinol vs. Control dogs (without heart failure) was evaluated on Myocardial oxygen consumption in heart failure dogs (-49%, p=0.002). Intravenous allopurinol decreased myocardial oxygen consumption by 49% (P=0.002) and increased mechanical efficiency by 122% (P=0.04) in dogs with pacing-induced heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: